External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer.
暂无分享,去创建一个
Cornelis J H van de Velde | Caroline Seynaeve | Sabine Siesling | Gerrit-Jan Liefers | A. D. de Craen | C. Seynaeve | C. V. D. van de Velde | J. Nortier | E. Bastiaannet | S. Siesling | R. Westendorp | G. Liefers | Anton J M de Craen | Willemien van de Water | Mandy Kiderlen | Esther Bastiaannet | Rudi G J Westendorp | Johan W R Nortier | W. van de Water | M. Kiderlen | C. J. van de Velde
[1] B. Psaty,et al. Generalizability of the results of randomized trials. , 2008, Archives of internal medicine.
[2] H. Putter,et al. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries , 2010, The British journal of surgery.
[3] Kelvin K. W. Chan,et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials , 2006, BMC Cancer.
[4] J. Knudsen,et al. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side‐effect management 1 , 2007, Journal of clinical pharmacy and therapeutics.
[5] R. Weichselbaum,et al. Predictors of competing mortality in early breast cancer , 2010, Cancer.
[6] H. Cohen,et al. Barriers to clinical trial participation by older women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.
[8] M. Aapro,et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] C. Seynaeve,et al. Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study. , 2013, Breast.
[10] H. Putter,et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. , 2012, JAMA.
[11] Ahmedin Jemal,et al. Breast cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[12] Joy H. Lewis,et al. Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[14] H. Putter,et al. Competing risks in epidemiology: possibilities and pitfalls. , 2012, International journal of epidemiology.
[15] A. D. de Craen,et al. Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis , 2013, Breast Cancer Research and Treatment.
[16] P. Harteloh,et al. The reliability of cause-of-death coding in The Netherlands , 2010, European Journal of Epidemiology.
[17] L. Siu,et al. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Jemal,et al. Breast Cancer Statistics , 2013 .
[19] H Putter,et al. Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.
[20] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .
[21] A. Kiss,et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. , 2007, JAMA.
[22] Hein Putter,et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial , 2011, The Lancet.
[23] Donna M. Zulman,et al. Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials , 2011, Journal of General Internal Medicine.
[24] M. Chou,et al. Diversity in death certification: a case vignette approach. , 2001, Journal of clinical epidemiology.
[25] J. Crawford,et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials , 2002, Cancer.
[26] Jan P Vandenbroucke,et al. When are observational studies as credible as randomised trials? , 2004, The Lancet.
[27] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[28] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[29] C. vanPraag,et al. Rapportage minderheden 1995 , 1995 .